Italian API maker rebounds; Patheon takes opioid work;

> Montreal-based Labopharm (TSX: DDS; NASDAQ: DDSS) says that Italy's Gruppo Angelini, which makes the active ingredient for the once-daily depression treatment Trazodone, has resolved all manufacturing process issues raised by the FDA. Announcement

> In an agreement between QRxPharma (ASX: QRX and OTCQX: QRXPY) and Patheon (TSX:PTI), the latter will manufacture clinical supplies of QRxPharma's controlled-release Dual-Opioid formulation for 12-hour pain relief. Release

> The University of Iowa Pharmaceuticals (UIP) has been cleared by the FDA to manufacture and test an aseptically filled, sterile prescription drug for a commercial client. Release

> TruScan 1.3.0, Ahura Scientific's handheld Raman spectrometer for raw material identification and finished product authentication, now boasts availability in the Chinese and German languages. Release

> Schering-Plough says it will expand a Montreal manufacturing facility to the tune of $28 million. Article

And Finally... The Top 15 Women in Pharma. Start slideshow ⇒

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.